Tonix Pharmaceuticals Holding Corp (NAS:TNXP)
$ 0.1883 -0.0005 (-0.26%) Market Cap: 35.19 Mil Enterprise Value: 15.65 Mil PE Ratio: 0 PB Ratio: 0.39 GF Score: 31/100

Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio Transcript

Feb 23, 2023 / NTS GMT
Release Date Price: $146.22 (+1.02%)
Natalie Stoberman

Welcome to our Proactive Studios. I'm Natalie Stoberman, joined by the CEO of Tonix Pharmaceuticals. Seth Lederman. Seth, thank you for joining us again.

Seth Lederman
Tonix Pharmaceuticals Holding Corp. - Co-Founder, CEO & Chairman

Thank you for having me [on].

Questions & Answers

Natalie Stoberman

It's my pleasure, especially when there's big news on the table like an acquisition, what are the details of the company's acquisition of Healion Bio?

Seth Lederman
Tonix Pharmaceuticals Holding Corp. - Co-Founder, CEO & Chairman

We bought Healion because it has really interesting, broad spectrum antiviral technology. And there's a history between our Head of Infectious Disease Research, Sina Bavari, and Healion. Sina Bavari was a Co-Founder of Healion and in fact, the Scientific Founder of Healion. He did that after he left his position as Head of R&D at the United States Army Medical Research Institute for Infectious Disease, which is called USAMRIID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot